This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

9 Meters Biopharma Resultados de beneficios anteriores

Pasado controles de criterios 0/6

9 Meters Biopharma's earnings have been declining at an average annual rate of -15.8%, while the Pharmaceuticals industry saw earnings growing at 7.6% annually.

Información clave

-15.8%

Tasa de crecimiento de los beneficios

47.6%

Tasa de crecimiento del BPA

Crecimiento de la industria Pharmaceuticals	7.3%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera	n/a
Margen neto	n/a
Última actualización de beneficios	31 Mar 2023

Actualizaciones de resultados anteriores recientes

No hay actualizaciones

Recent updates

Desglose de ingresos y gastos

Cómo gana y gasta dinero 9 Meters Biopharma. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

DB:2Q3A Ingresos, gastos y beneficios (USD Millions)
Fecha	Beneficios	Gastos G+A	Gastos de I+D
31 Mar 23	-46	11	32
31 Dec 22	-44	11	31
30 Sep 22	-41	11	29
30 Jun 22	-46	11	29
31 Mar 22	-43	10	27
31 Dec 21	-37	9	22
30 Sep 21	-32	8	18
30 Jun 21	-27	8	17
31 Mar 21	-63	10	12
31 Dec 20	-61	10	11
30 Sep 20	-65	10	13
30 Jun 20	-66	11	12
31 Mar 20	-26	9	15
31 Dec 19	-27	10	14
30 Sep 19	-22	10	10
30 Jun 19	-14	9	4
31 Mar 19	-14	9	2
31 Dec 18	-24	11	8
30 Sep 18	-22	10	7
30 Jun 18	-24	10	9
31 Mar 18	-23	10	9
31 Dec 17	-12	7	4
30 Sep 17	-11	7	4

Ingresos de calidad: 2Q3A is currently unprofitable.

Margen de beneficios creciente: 2Q3A is currently unprofitable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: 2Q3A is unprofitable, and losses have increased over the past 5 years at a rate of 15.8% per year.

Acelerando crecimiento: Unable to compare 2Q3A's earnings growth over the past year to its 5-year average as it is currently unprofitable

Beneficios vs. Industria: 2Q3A is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (11%).

Rentabilidad financiera

Alta ROE: 2Q3A's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.

This company listing is no longer active

9 Meters Biopharma Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

Recent updates

9 Meters Biopharma Receives Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Rule

9 Meters Biopharma, Inc. Appoints Bethany Sensenig as Interim CEO

9 Meters Biopharma, Inc. Announces the Resignation of John Temperato as President

9 Meters Biopharma, Inc. Announces Phase 3 Study of Vurolenatide in Short Bowel Syndrome

High number of new and inexperienced directors

9 Meters Biopharma Announces Positive Final Results from Phase 2 VIBRANT Study and Successful End-of-Phase 2 Meeting with FDA for Vurolenatide in Short Bowel Syndrome

9 Meters Biopharma Announces Positive Preliminary Results from Phase 2 Study of Vurolenatide in Short Bowel Syndrome

9 Meters Biopharma, Inc. announced that it expects to receive $70 million in funding

9 Meters Biopharma, Inc., Annual General Meeting, Jun 22, 2022

High number of new and inexperienced directors

President recently bought €50k worth of stock

9 Meters Biopharma Provides Clinical Update on Late-Stage Pipeline Products Vurolenatide for Short Bowel Syndrome and Larazotide for Celiac Disease

Independent Chairman recently bought €84k worth of stock

9 Meters Biopharma, Inc. Announces Initiation of Phase 2 Vibrant Study of Vurolenatide for Short Bowel Syndrome

9 Meters Biopharma, Inc. Announces Publication in Journal of Clinical Investigation Describing Successful Use of Larazotide for Treating Multisystem Inflammatory Syndrome in Children Resulting from Covid-19 Infection

9 Meters Biopharma, Inc. Receives USAN Approval to Use the Designated Nonproprietary Name Vurolenatide for Its Long-Acting GLP-1 Agonist for Short Bowel Syndrome

Forecast to breakeven in 2024

9 Meters Biopharma Hosting Key Opinion Leader Webinar on Short Bowel Syndrome and NM-002 Program Update

9 Meters Biopharma Inc Appoints Michael Rice as Board of Director

New 90-day high: €1.86

9 Meters Biopharma, Inc. Announces the Resignation of Nissim Darvish as Director

Independent Director has left the company

New 90-day high: €1.22

New 90-day high: €1.19

9 Meters Biopharma, Inc. has completed a Follow-on Equity Offering in the amount of $30.000001 million.

New 90-day high: €0.85

9 Meters Biopharma Announces Positive Preclinical Data for NM-102, a Gut Microbiome Modulator in an Immune Checkpoint Inhibitor Failure Model

Independent Chairman recently bought €81k worth of stock

New 90-day high - €0.74

Innovate Biopharmaceuticals, Inc. (NasdaqCM:INNT) completed the acquisition of RDD Pharma, Ltd. from OrbiMed Israel Partners managed by OrbiMed Advisors, L.L.C. and others.

9 Meters Biopharma, Inc.(NasdaqCM:NMTR) dropped from Russell Microcap Index

Desglose de ingresos y gastos

Historial de beneficios e ingresos

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Rentabilidad financiera

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado